{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:07:44Z","timestamp":1772892464148,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00734","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T21:11:48Z","timestamp":1757106708000},"page":"e00734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two roads diverged in multiple sclerosis: When is switching therapy effective?"],"prefix":"10.1016","volume":"22","author":[{"given":"Anthony T.","family":"Reder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurot.2025.e00734_bib1","article-title":"Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: insights from na\u00efve and switch patients","volume":"22","author":"Chisari","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"337","key":"10.1016\/j.neurot.2025.e00734_bib2","first-page":"1","article-title":"Cancer risk and multiple sclerosis: evidence from a large Italian cohort","volume":"10","author":"D\u2019Amico","year":"2019","journal-title":"Front Neurol"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00734_sref3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN\u03b2-1b trial","volume":"78","author":"Goodin\u2217","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00734_bib4","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200075","article-title":"Increased percentage of CD8+CD28- regulatory T cells with fingolimod therapy in multiple sclerosis","volume":"10","author":"Houston","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00734_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/135245850100700401","article-title":"Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS","volume":"7","author":"Chen","year":"2001","journal-title":"Mult Scler"},{"issue":"6578","key":"10.1016\/j.neurot.2025.e00734_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00734_sref7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ebiom.2019.09.059","article-title":"Interferon-\u03b2 corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection","volume":"49","author":"Feng\u2217","year":"2019","journal-title":"Lancet EBioMedicine"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00734_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jir.2024.0032","article-title":"Alternative splicing of genes is excessive in multiple sclerosis and not linked to gene expression levels: dysregulation is corrected by IFN-\u03b2","volume":"44","author":"Reder","year":"2024","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.neurot.2025.e00734_bib9","article-title":"IFN-\u03b2 therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses","author":"Li\u2217","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00734_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578328","article-title":"Novel biomarkers and interferon signature in secondary progressive multiple sclerosis","volume":"389","author":"Fogel","year":"2024","journal-title":"J Neuroimmunol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:30:05Z","timestamp":1763638205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925002120"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00734","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two roads diverged in multiple sclerosis: When is switching therapy effective?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00724","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00734"}}